Reports Q1 revenue $1.4M, consensus $4.25M. “The first quarter reflected continued execution across CRISPR Therapeutics (CRSP)’ platform,” said Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics. “We expanded zugo-cel into new autoimmune indications and advanced multiple in vivo liver-directed programs toward the clinic, while CASGEVY continued its momentum. With a strengthened balance sheet and multiple upcoming milestones, we believe 2026 will be a defining year for CRISPR Therapeutics.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Reaffirming Buy on CRISPR Therapeutics: Conference Engagement and Gene-Editing Leadership Support Attractive Risk‑Reward
- Cathie Wood’s ARK Invest Dumps $2.1M Worth of META Shares; Stock Sinks
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler
- Crispr Therapeutics Completes $600 Million Convertible Notes Offering